Wang Y - Search Results

1

PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity.

Wei J, Luo C, Wang Y, Guo Y, Dai H, Tong C, Ti D, Wu Z, Han W. Wei J, et al. J Immunother Cancer. 2019 Aug 7;7(1):209. doi: 10.1186/s40425-019-0685-y. J Immunother Cancer. 2019. PMID: 31391096 Free PMC article.

2

Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy.

Dai H, Wang Y, Lu X, Han W. Dai H, et al. J Natl Cancer Inst. 2016 Jan 27;108(7):djv439. doi: 10.1093/jnci/djv439. Print 2016 Jul. J Natl Cancer Inst. 2016. PMID: 26819347 Free PMC article. Review.

3

Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer.

Feng K, Guo Y, Dai H, Wang Y, Li X, Jia H, Han W. Feng K, et al. Sci China Life Sci. 2016 May;59(5):468-79. doi: 10.1007/s11427-016-5023-8. Epub 2016 Mar 11. Sci China Life Sci. 2016. PMID: 26968708

4

Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects.

Guo Y, Wang Y, Han W. Guo Y, et al. J Immunol Res. 2016;2016:3850839. doi: 10.1155/2016/3850839. Epub 2016 Feb 21. J Immunol Res. 2016. PMID: 26998495 Free PMC article. Review.

5

Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo.

Song Y, Tong C, Wang Y, Gao Y, Dai H, Guo Y, Zhao X, Wang Y, Wang Z, Han W, Chen L. Song Y, et al. Protein Cell. 2018 Oct;9(10):867-878. doi: 10.1007/s13238-017-0384-8. Epub 2017 Mar 10. Protein Cell. 2018. PMID: 28284008 Free PMC article.

6

Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment.

Guo Y, Feng K, Wang Y, Han W. Guo Y, et al. Protein Cell. 2018 Jun;9(6):516-526. doi: 10.1007/s13238-017-0394-6. Epub 2017 Mar 13. Protein Cell. 2018. PMID: 28290053 Free PMC article. Review.

7

Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers.

Feng K, Liu Y, Guo Y, Qiu J, Wu Z, Dai H, Yang Q, Wang Y, Han W. Feng K, et al. Protein Cell. 2018 Oct;9(10):838-847. doi: 10.1007/s13238-017-0440-4. Epub 2017 Jul 14. Protein Cell. 2018. PMID: 28710747 Free PMC article. Clinical Trial.

8

Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers.

Guo Y, Feng K, Liu Y, Wu Z, Dai H, Yang Q, Wang Y, Jia H, Han W. Guo Y, et al. Clin Cancer Res. 2018 Mar 15;24(6):1277-1286. doi: 10.1158/1078-0432.CCR-17-0432. Epub 2017 Nov 14. Clin Cancer Res. 2018. PMID: 29138340 Clinical Trial.

9

Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy.

Zhang WY, Liu Y, Wang Y, Nie J, Guo YL, Wang CM, Dai HR, Yang QM, Wu ZQ, Han WD. Zhang WY, et al. Gene Ther. 2018 Jun;25(3):198-204. doi: 10.1038/s41434-017-0001-8. Epub 2018 Mar 29. Gene Ther. 2018. PMID: 29599530

10

Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.

Gao Z, Tong C, Wang Y, Chen D, Wu Z, Han W. Gao Z, et al. J Genet Genomics. 2019 Aug 20;46(8):367-377. doi: 10.1016/j.jgg.2019.06.007. Epub 2019 Aug 13. J Genet Genomics. 2019. PMID: 31466926

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

367,681 results

Search Page

Filters